



T-cell responses after COP Immunotherapy to be Presented at EAACI Congress 2017

- *Delineation of T cell responses after COP Immunotherapy in birch pollen allergic patients*

EPALINGES, Switzerland, June 13, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that new mechanistic data using its lead-product AllerT for the treatment of patients allergic to birch pollen, will be presented by Dr Pawel Gajdanowicz of the Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland at the EAACI Congress 2017 in Helsinki, Finland.

The studies reported were conducted in collaboration between “ALL-MED” Medical research Institute, Wrocław, the Department of Clinical Immunology, Wrocław Medical University and Anergis SA, on samples collected from a previous clinical trial during which birch allergic patients received either AllerT or placebo.

Today, AllerT is the only ultra-fast AIT treatment with demonstrated clinical efficacy in real-life field-based trials over two consecutive annual pollen seasons and with persistent statistically significant elevation in specific immunoglobulin G4 (IgG4) over four consecutive annual pollen seasons, without repeated treatment after the initial 2-month course.

Anergis SA is currently conducting a large-scale field-based trial with AllerT called ATIBAR, the results of which are expected to be available during Q3 2017.

Presentation Title: *"Delineation of T cell responses after COP Immunotherapy in birch pollen allergic patients"*

Presenter: *Pawel Gajdanowicz*

Time and Date: *Tuesday, June 20, 2017, 12.00 pm - 1.30 pm*

Session: *TPS 51 - Immune response and mechanisms of allergy*

Poster #: *1340*

Location: *Thematic Poster Exhibition, Messukeskus, Helsinki Finland*

* * *

About Anergis

Anergis SA is a Swiss biopharmaceutical company dedicated to the discovery and development of novel, ultra-fast, proprietary allergy immunotherapy products for the most prevalent allergies. Anergis' lead-product against birch pollen allergies, AllerT, is in Phase II clinical development. Two additional product candidates against ragweed pollen (AllerR) and house dust mite allergies (AllerDM) are in preclinical development. Anergis has raised over CHF 52 million from private and institutional investors, including BioMedInvest, Renaissance PME, Sunstone Capital, and WJFS, Inc.



About Allergies

Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world, affecting over 500 million people. The only curative therapy of allergies available today, known as “desensitization”, “allergy shots” or “Conventional Allergy Immunotherapy” (AIT), is the process of inducing tolerance to the allergen. It typically requires 3-5 years of treatment and exposes patients to the risk of serious side effects – in particular immediate (<30 min) anaphylactic reactions – which can be life-threatening. With its technology, Anergis is shaping the future of allergy treatment by developing therapeutic modalities that only require 2 months of treatment - compared to 3 to 5 years with currently marketed products.

About Ultra-fast Allergy Immunotherapy and AllerT

AllerT is Anergis’ ultra-fast allergy immunotherapy (AIT) against birch pollen allergy originating from the company’s proprietary Contiguous Overlapping Peptide (COP) technology platform. COPs are long synthetic peptides that include the full amino acid sequence of one or more natural allergens, which are devoid of the IgE epitopes responsible for the risk of anaphylaxis during immunotherapy with allergens. COP allergy immunotherapy is “ultra-fast” because it only requires a single, 2-month course of treatment to induce long-lasting allergy symptom relief – without repeated treatment in following years.